Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker
- Status
- TERMINATED
- Phase
- PHASE2
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
- Status
- COMPLETED
- Phase
- PHASE1
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Genetic Predictors of Benefit to Pembrolizumab
- Status
- TERMINATED
- Phase
- PHASE2
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
- Status
- COMPLETED
- Phase
- PHASE2
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE1
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC
- Status
- COMPLETED
- Phase
- PHASE2